What is Concord Biotech Ltd (CONCORDBIO) share price today?

Concord Biotech Ltd (CONCORDBIO) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/CONCORDBIO for the latest live price, technical analysis, and AI-powered insights.

How to analyse CONCORDBIO stock?

VestAI provides comprehensive CONCORDBIO stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Concord Biotech Ltd in?

Concord Biotech Ltd (CONCORDBIO) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Concord Biotech Ltd

Name: Concord Biotech Ltd (CONCORDBIO) Financial Metrics
Creator: VestAI
License: https://www.vestai.io/terms

CONCORDBIO

NSE· Healthcare

₹1,256.10

-0.30 (-0.02%)

52W Low · ₹987.0052W High · ₹1,905.00

Near 52W Low

Market Cap

₹13061.33L Cr

Volume

27.9K

Prev Close

₹1,248.50

ISIN

INE338H01029

Orion Score

Fundamentals-based quality & risk · not a recommendation

63/100

Watch

Concord Biotech Ltd scores 63/100 (Watch) on the Orion Score — strong business quality (81), poor growth (25), strong balance-sheet safety (94) and rich valuation (21). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Short track record (3 yrs of data)

Forensic accounting

Piotroski F 4/9Altman Z Safe(16.06)Beneish M Clean(-2.56)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

49/100

Neutral

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.00x — lean balance sheet

QUALITY

Average

ROCE 14.8% — decent returns

MOMENTUM

Neutral

RSI 45.8 — consolidating

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio: 50.46
ROCE: 14.76%
ROE (1Y): 13.54%
D/E Ratio: 0.00x
OPM: 30.36%
TTM EPS: ₹24.74
Dividend Yield: 60.00%
Qtrly Sales: ₹326.08 Cr
Qtrly Profit: ₹88.79 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q4 2026	₹326.08	₹88.79	30.4%	₹8.46
Q3 2026	₹277.77	₹63.64	28.9%	₹6.08
Q2 2026	₹247.06	₹63.06	28.4%	₹6.03
Q1 2026	₹203.99	₹44.06	21.4%	₹4.21
Q4 2025	₹429.88	₹140.39	40.9%	₹13.42

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2026	₹1,054.89	₹260.91	₹419.39	27.8%
FY 2025	₹1,200.09	₹371.64	₹549.46	37.7%
FY 2024	₹998.06	₹308.1	₹468.71	38.7%
FY 2023	₹830.63	₹240.09	₹380.56	36.7%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
CONCORDBIO ★	₹13,061 Cr	50.46	14.76%	13.54%	0.00x	30.36%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹88,148 Cr	25.39	12.55%	9.93%	0.21x	15.11%
ASTERDMAster DM Quality	₹68,390 Cr	104.34	8.93%	10.07%	0.46x	13.98%
ABBOTINDIAAbbott India Limited	₹59,509 Cr	38.28	36.31%	34.46%	0.04x	27.01%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹2,034.25	₹1,700.71	₹1,513.98	₹1,312.8
Equity	₹1,812.72	₹1,526.65	₹1,290	₹1,103.22
Total Debt	₹2.97	₹9.74	₹31.55	₹62.49
Cash	₹0.9	₹15.14	₹3.5	₹0.67
Net Debt	—	—	₹27.74	₹59.92
Working Capital	₹951.18	₹754.08	₹535.86	₹477.5

Shareholding Pattern

Q1 FY2027

Promoter

74.26%

FII

6.9%

DII

5.64%

Public

13.2%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	74.26% ↓	6.9% ↓	5.64% ↓	13.2% ↑
Q4 FY2026	74.65% ↑	6.94% ↓	5.68% ↓	12.73% ↓
Q3 FY2026	44.08%	7.58% ↓	9.58% ↑	38.75% ↑
Q2 FY2026	44.08%	8.03% ↓	9.55% ↑	38.32% ↑
Q1 FY2026	44.08%	9.1% ↓	8.85% ↓	37.94% ↑
Q4 FY2025	44.08%	9.35% ↑	9.16% ↓	37.41% ↓
Q3 FY2025	44.08%	8.33% ↑	9.65% ↓	37.93% ↓
Q2 FY2025	44.08%	8.1%	9.89%	37.95%

Corporate Actions

Ex-Date	Action	Details
2026-07-24	DIVIDEND	Dividend - Rs 7.55 Per Share

Smart Money Holdings

Q4 FY2025

Investor	Shares Held	Portfolio %	Change
Rekha JJ	8,00,000	7.21%	—

Funds Holding This Stock

43 mutual fund schemes

SBI Healthcare Opportunities Fund Direct Plan GrowthSBI

1.66%

₹76 Cr

DSP Healthcare Fund Direct GrowthDSP

1.58%

₹52 Cr

Baroda BNP Paribas Health and Wellness Fund Direct GrowthBARODABNPPARIBASMUTUALFUND_MF

1.45%

₹8 Cr

ITI Flexi Cap Fund Direct GrowthITI

1.00%

₹13 Cr

Baroda BNP Paribas Innovation Fund Direct GrowthBARODABNPPARIBASMUTUALFUND_MF

0.96%

₹8 Cr

Edelweiss Small Cap Fund Direct GrowthEDELWEISS

0.79%

₹49 Cr

Tata India Pharma & Healthcare Fund Direct GrowthTATA

0.77%

₹11 Cr

DSP Small Cap Direct Plan GrowthDSP

0.76%

₹140 Cr

Bandhan Healthcare Fund Direct GrowthIDFC

0.68%

₹2 Cr

Invesco India Aggressive Hybrid Fund Direct GrowthINVESCO

0.58%

₹4 Cr

Analyse CONCORDBIO with Orion AI

Ask: "Is Concord Biotech Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Concord Biotech Ltd (CONCORDBIO) Stock

Concord Biotech Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE338H01029. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.